Arcutis Biotherapeutics Inc.

10/18/2024 | Press release | Distributed by Public on 10/18/2024 06:22

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Derm